Have a personal or library account? Click to login
Cardiological Monitoring – A Cornerstone for Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 Outcome: A Case Report and a Review from the Literature Cover

Cardiological Monitoring – A Cornerstone for Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 Outcome: A Case Report and a Review from the Literature

Open Access
|Nov 2022

References

  1. European Centre for Disease Prevention and Control. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children. ECDC:Stockholm. 2020;15 May.
  2. Balasubramanian S, Nagendran TM, Ramachandran B, Ramanan AV. Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab. Indian Pediatr. 2020;57(7):681–3.
  3. Marginean C, Melit L, Sasaran M. Pediatric obesity–a potential risk factor for systemic inflammatory syndrome associated to COVID-19, a case report. Front Pediatr. 2021;9:493.
  4. Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J, Waters G, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health. 2020;4(9):669–77.
  5. Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS) - guidance for clinicians [Internet]. RCPCH. [cited 2021 Mar 7]. Available from: https://www.rcpch.ac.uk/resources/paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims-guidance
  6. HAN Archive - 00432 | Health Alert Network (HAN) [Internet]. 2020 [cited 2021 Mar 7]. Available from: https://emergency.cdc.gov/han/2020/han00432.asp
  7. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19 [Internet]. [cited 2021 Mar 7]. Available from: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
  8. Mărginean CO, Meliţ LE, Chinceşan M, Mureşan S, Georgescu AM, Suciu N, et al. Communication skills in pediatrics - the relationship between pediatrician and child. Medicine (Baltimore). 2017;96(43):e8399.
  9. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet Lond Engl. 2020;395(10239):1771–8.
  10. Belhadjer Z, Méot M, Bajolle F, Khraiche D, Legendre A, Abakka S, et al. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic. Circulation. 2020;142(5):429–36.
  11. Bhat CS, Gupta L, Balasubramanian S, Singh S, Ramanan AV. Hyperinflammatory Syndrome in Children Associated With COVID-19: Need for Awareness. Indian Pediatr. 2020;57(10):929–35.
  12. Tullie L, Ford K, Bisharat M, Watson T, Thakkar H, Mullassery D, et al. Gastrointestinal features in children with COVID-19: an observation of varied presentation in eight children. Lancet Child Adolesc Health. 2020;4(7):e19–20.
  13. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020;324(3):259–69.
  14. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet Lond Engl. 2020;395(10237):1607– 8.
  15. Sperotto F, Friedman KG, Son MBF, VanderPluym CJ, Newburger JW, Dionne A. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr. 2021;180(2):307–22.
  16. Grimaud M, Starck J, Levy M, Marais C, Chareyre J, Khraiche D, et al. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Ann Intensive Care. 2020;10(1):69.
  17. Burns JC, Franco A. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol. 2015;11(7):819–25.
  18. Lo MS, Newburger JW. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis. 2018;21(1):64–9.
  19. Mărginean CO, Meliț LE, Gozar L, Mărginean CD, Mărginean MO. Incomplete Refractory Kawasaki Disease in an Infant-A Case Report and a Review of the Literature. Front Pediatr. 2018;6:210.
  20. Mărginean CO, Meliţ LE, Mărginean MO. The peculiarities of Kawasaki disease at the extremes of age: Two case reports. Medicine (Baltimore). 2019;98(42):e17595.
  21. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet Lond Engl. 2020;395(10229):1033–4.
  22. Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol. 2020;20(6):345–6.
DOI: https://doi.org/10.2478/jccm-2022-0022 | Journal eISSN: 2393-1817 | Journal ISSN: 2393-1809
Language: English
Page range: 273 - 278
Submitted on: Oct 27, 2021
|
Accepted on: Aug 30, 2022
|
Published on: Nov 12, 2022
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2022 Lorena Elena Melit, Oana Marginean, Tudor Fleșeriu, Alina Negrea, Maria Oana Săsăran, Simina Ghiraghosian-Rusu, Andrei Călin Dragomir, Mirela Oiaga, Carmen Șuteu, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.